Mutual of America Capital Management LLC Acquires Shares of 367,421 Avantor, Inc. (NYSE:AVTR)

Mutual of America Capital Management LLC bought a new position in Avantor, Inc. (NYSE:AVTR) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 367,421 shares of the company’s stock, valued at approximately $9,505,000. Mutual of America Capital Management LLC owned about 0.05% of Avantor at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Empowered Funds LLC purchased a new stake in Avantor during the 1st quarter valued at about $250,000. SG Americas Securities LLC purchased a new stake in shares of Avantor during the first quarter valued at approximately $159,000. Intech Investment Management LLC grew its holdings in shares of Avantor by 60.2% during the first quarter. Intech Investment Management LLC now owns 28,554 shares of the company’s stock valued at $730,000 after buying an additional 10,727 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Avantor by 45.8% during the first quarter. Acadian Asset Management LLC now owns 22,678 shares of the company’s stock valued at $579,000 after acquiring an additional 7,120 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in Avantor in the 1st quarter worth approximately $1,242,000. 95.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.50% of the company’s stock.

Avantor Price Performance

Shares of Avantor stock opened at $20.74 on Monday. The stock has a market cap of $14.12 billion, a P/E ratio of 45.09, a P/E/G ratio of 2.51 and a beta of 1.35. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The stock’s fifty day moving average is $24.52 and its 200 day moving average is $24.00. Avantor, Inc. has a one year low of $19.11 and a one year high of $28.00.

Wall Street Analysts Forecast Growth

Several analysts have commented on AVTR shares. TD Cowen increased their target price on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Morgan Stanley increased their price objective on Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Barclays decreased their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. UBS Group dropped their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, October 8th. Finally, Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Avantor currently has a consensus rating of “Moderate Buy” and an average price target of $27.57.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.